Skip to main content
OpenTrials
Completed

NCT Number: NCT01126034

Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention

The investigators hypothesized that:

1) an intervention targeted at the prescribing physician would increase the rate of a metoclopramide discontinuation among patients prescribed the medication for questionable or unclear indications; and 2) the discontinuation would be durable.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastroesophageal Reflux Disease Deglutition Disorders Diabetic Gastroparesis Digestive System Diseases Esophageal Diseases Esophageal Motility Disorders Gastroesophageal Reflux Gastrointestinal Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Pennsylvania Center for Clinical Epidemiology and Biostatistics

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Physicians at University of Pennsylvania Health System who ordered an active metoclopramide prescription with a questionable indication.

Exclusion criteria

  • Physicians-in-training (e.g., residents, fellows)
  • Physicians how were investigators on this study
  • Physicians serving on the the University of Pennsylvania Drug Use and Effects Committee or Information Technology Oversight Board

Treatment and study plan

Intervention letter

Other

Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:

  • The name and medical record # of the patients involved
  • Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy
  • A reminder of the adverse effect of long-term metoclopramide therapy
  • A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients
  • A request that the physician document the discontinuation trial in the electronic medical record

Primary outcomes

  1. Discontinuation of metoclopramide therapy

    Time frame: 12 weeks after intervention period

    Twelve weeks after the intervention period, we searched the medical records of patients in the intervention and non-intervention groups to determine whether discontinuation of metoclopramide therapy had taken place.

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
May 19, 2010
Registry last updated
Dec 4, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.